In diet-induced NAFLD mice, IBAT inhibitor IMB17-15 is reported to alter the intestinal BA composition and mediate intestinal FGF15/19 pathway, which contributes to the improvement of NAFLD phenotype in mice (Ge et al., 2019). Here, SLC10A2 is linked to metabolic dysfunction-associated steatotic liver disease.